CHAIR — DEPARTMENT OF FAMILY PRACTICE — A.B. Chandler Medical Center

The University of Kentucky College of Medicine invites applications for the position of Chair of the Department of Family Practice. Reporting to the Dean of the College of Medicine, the successful candidate must demonstrate strong leadership skills and an ability to foster excellence in teaching, patient care and research. The Department is composed of five general divisions: Residency Program, Undergraduate Education, Geriatrics, Research and Administration.

The Faculty is committed to the education of family practice residents. The fully accredited residency program, which currently serves 24 residents, has gained national attention by offering an "accelerated" residency program to selected students. A new 1-2 Family Practice Residency Program has been approved and is being developed in Hazard, Kentucky.

In the fall of 1992, the Department of Family Practice will be moving to its new Center. Located on the campus of the University of Kentucky, both the College of Medicine and Department of Family Practice offer a unique learning and working environment.

Applications should be submitted as soon as possible. Review of applications will begin on February 15, 1992, and continue until the position is filled. Female and minority candidates are encouraged to apply. In consideration of dual careers, the University has a partner relocation assistance program. All interested applicants should send a letter of application, references and curriculum vitae with bibliography to:

Andrew Fried, M.D.
Chair, Search Committee
University of Kentucky, College of Medicine, Department of Diagnostic Radiology
Room HX 317, Rose Street, Lexington, KY 40536-0084

The University of Kentucky is an Affirmative Action, Equal Opportunity Employer.

NORTH CAROLINA
ATLANTA, GEORGIA

PRIMARY CARE - URGENT CARE

The Southeast Permanente Medical Group is a physician-owned and managed multi-specialty group which provides care to the members of the Kaiser Permanente Medical Care Program. Opportunities are available for Family Physicians to practice primary care and/or urgent care in our Raleigh, NC and Atlanta, GA medical offices. Excellent salary/benefits including professional liability, retirement, and shareholder opportunity.

For more information contact:

In North Carolina:
Phyllis Kline
TSPMG, Dept. AD053
3120 Highwoods Blvd.
Raleigh, NC 27604-1018
(800) 277-2764

In Georgia:
Linda McIntyre
TSPMG, Dept. AD053
3355 Lenox Rd., Ste. 1000
Atlanta, GA 30326
(800)-877-0409

KAISER PERMANENTE
Good People Good Medicine. AA/EOE.
Many physicians are finding it difficult to keep current on the effectiveness and safety of prescribed products.

Drug Therapy, Volume 8 can help you review changes in drug use, the implications of using drugs in combination, and the comparative efficacy of different drugs.

Drug Therapy, Volume 8 includes 24 review articles originally published in the New England Journal of Medicine from 1985 to 1990, plus related Correspondence and Addenda by the original authors, providing updates from new research and clinical experience.

Drug Therapy, Volume 8 © 1991. Edited by John A. Oates, M.D. and Alastair J.J. Wood, M.D., Department of Medicine, Vanderbilt University School of Medicine 300 pages, including index and over 75 charts & illustrations.

ANTIIARRHYTMICS
(Encainide, Flecaïnine, Tocainide, Amiodarone, Mexiletine)

VASODILATORS AND ANTITHROMBOTICS
(Combined Beta-Adrenergic and Calcium-Entry Blockade in Angina Pectoris, Nitrate Therapy in Stable Angina Pectoris, Converting-Enzyme Inhibitors, Tissue Plasminogen Activator, Dipyridamole)

ANTIBIOTICS
(Beta-Lactam Antibiotics, Bactericidal Activity as a Monitor of Antibiotic Therapy, Antimicrobial Prophylaxis)

ANTICANCER DRUGS
(Etoposide, Ketoconazole as an Inhibitor of Steroid Production)

BRONCHODILATORS
Ipratropium Bromide, New Approach to the Treatment of Asthma)

OTHERS
(Drug Therapy in the Elderly, Cyclosporine, Oral Hypoglycemic Agents, AZT (Zidovudine) and Related Dideoxynucleosides, Physiologic Replacement of Insulin, HMG-CoA Reductase Inhibitors, Cigarette Smoking and Nicotine Addiction)
CARE plants the most wonderful seeds on earth.

Seeds of self-sufficiency that help starving people become healthy, productive people. And we do it village by village by village. Please help us turn cries for help into the laughter of hope.

1-800-521-CARE
**Drug Interactions:** Catecholamine-depleting drugs may have additive effects when given with β-blockers. Observe patients treated with both agents closely for evidence of marked Bradyarrhythmia or hypotension which may present as vertigo, syncope, presyncope, or orthostatic changes in blood pressure without compensatory tachycardia. Exaggerated hypotensive responses and hypotensive collapse may be reversed with β-adrenergic antagonists or α-adrenergic stimulants, including those in OTC cold remedies and vasoconstrictive nasal drops. Nonsteroidal anti-inflammatory drugs may further change the hemodynamic effects of beta-blockers.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Chronic oral toxicity studies in rats and mice, at doses 10 times the maximum recommended human dose, did not indicate carcinogenic potential for SECTRAL. Diacetoilol, the major metabolite in man, was without carcinogenic potential in rats at doses up to 1800 mg/kg/day. SECTRAL and diacetoilol showed no evidence of mutagenic potential in the Ames Test. There was no significant impact on reproductive performance or fertility was found in rats following SECTRAL or diacetoilol doses of up to 240 or 1000 mg/kg/day, respectively.

**Potentially Serious Effects:** Teratogenic Effects: No teratogenic effects were seen in rat or rabbit reproduction studies utilizing SECTRAL doses that were, respectively, approximately 31.5 and 6.8 times the maximum recommended human dose. At this dose in the rabbit, slight decrease in postnatal weight gain rates was noted. However, these decreases were not considered to be a result of maternal toxicity (evidenced by reduced food intake, lowered rate of body weight gain, mortality). Diacetoilol studies (doses up to 450 mg/kg/day in rats and up to 1000 mg/kg/day in rabbits) showed no evidence of fetal harm other than a significant elevation in postimplantation loss with 450 mg/kg/day, a level at which food consumption and body weight gain were reduced in rabbit dams; there was a statistically significant increase in incidence of bilateral microphthalmia in fetal mice from dams treated with 1800 mg/kg/day. There are no adequate and well controlled trials in pregnant women; SECTRAL should be used during pregnancy only if potential benefit justifies risk to the fetus.

**Nonteratogenic Effects:** Human studies indicate that acebutolol and diacetoilol cross the placenta. Neonates of mothers who received acebutolol during pregnancy have not shown any adverse effects. See PRECAUTIONS section for more information.

**Labor and Delivery:** Effect on labor and delivery in pregnant women is unknown. Animal studies have shown no effect of SECTRAL on the usual course of labor and delivery.

**Nursing Mothers:** Acebutolol and diacetoilol appear in breast milk (milk: plasma ratio 0.7:1 and 1.2:1, respectively). Use nursing mothers not recommended.

**Pediatric Use:** Safety and effectiveness in children have not been established.

**ADVERSE REACTIONS:** SECTRAL is well tolerated in properly selected patients. Minor adverse effects have been mild, not requiring therapy discontinuation, and tended to decrease as treatment duration increases.

The incidence of treatment-related side effects (volunteers and elicited) derived from 266 hypertensive patients controlled clinical trials in patients with hypertension, angina and arrhythmia follows. Numbers represent percentage incidence for SECTRAL (N = 1002) versus placebo (N=314), respectively:

**Cardiovascular:** Cerebral: Headache 2%, 1%. Edema 2%, 1%. Dizziness 2%, 1%. Palpitations 3%, 1%. Paresthesia 3%, 1%. Syncope 3%, 1%. Paroxysmal tachycardia 0.3%, 0.1%. Carotid sinus syncope 0.3%, 0.1%. Torsades de pointes 0.1%, 0.

**Respiratory:** Coughing 3%, 0.1%. Dyspnea 3%, 0.1%. Eosinophilia 0.1%, 0.1%. Infection 1%, 0.1%. Anaphylaxis 0.1%, 0.1%. Pulmonary edema 0.1%, 0.1%

**Sensory:** Neurosensorial: Vertigo 0.3%, 0.1%. Photophobia 0.3%, 0.1%

**Musculoskeletal:** Myalgia 0.1%, 0.1%

**General:** Malaise 2%, 0.1%

**Genitourinary:** Dysuria 0.1%, 0.1%

**Skin:** Urticaria 0.1%, 0.1%

**Pregnancy:** The adverse effects listed below are not included in the following table:

<table>
<thead>
<tr>
<th>Body System</th>
<th>400 mg/day</th>
<th>800 mg/day</th>
<th>1200 mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>(N = 132)</td>
<td>(N = 63)</td>
<td>(N = 71)</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>5%</td>
<td>3%</td>
<td>1%</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>3%</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>3%</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Central Nervous System</td>
<td>9%</td>
<td>3%</td>
<td>17%</td>
</tr>
<tr>
<td>Respiratory</td>
<td>1%</td>
<td>5%</td>
<td>6%</td>
</tr>
<tr>
<td>Skin</td>
<td>1%</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Special Senses</td>
<td>2%</td>
<td>3%</td>
<td>1%</td>
</tr>
<tr>
<td>Genitourinary</td>
<td>2%</td>
<td>3%</td>
<td>1%</td>
</tr>
</tbody>
</table>

**Potential Adverse Effects:** Certain adverse effects not listed above have been reported with other β-blockers and should be considered as potential adverse effects of SECTRAL. CNS: Reversible mental depression progressing to catatonia, an acute syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, increased intracranial pressure, rare instances of visual hallucinations, psychomimics. Cardiovascular: Intensification of AV block (see CONTRAINDICATIONS). Allergic: Arthralgia, pruritus, rash, fever with aching and sore throat, laryngitis, pharyngitis, respiratory distress. Hematologic: Agranulocytosis, nonthrombocytopenic and thrombocytopenic purpura. Gastrointestinal: Mesenteric arterial thrombosis, ischemic colitis. Miscellaneous: Reversible alopecia, Peyronie's disease. The olomucocutaneous syndrome associated with proctitis has not been reported with SECTRAL. Keep at room temperature, Approximately 25°C (77°F).

| 3482-6  | 62/189 |

©1991 Wyeth Ayerst Laboratories